• Discovering & developing proprietary prodrugs

    Our products have improved properties over approved drugs and address unmet medical needs in large, established markets.

  • Creating a diverse pipeline of prodrug therapeutics

    We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

  • Decades of experience in devising elegant solutions

    KemPharm® continues to implement its LAT® technology to create prodrugs that are new molecules by chemically attaching ligand(s) to the parent drug.

  • Innovation that Makes a Difference

    Learn more about how KemPharm® is applying its LAT® technology to discover and develop proprietary prodrugs to treat serious medical conditions, including the high need areas of idiopathic hypersomnia (IH) and other CNS/rare diseases.

  • FOCUSEDONATTENTION

    Learn more about how KemPharm® is applying their LAT® technology to create improved ADHD therapies. See the pipeline page for information on the research and development of prodrugs.

Products & Possibilities

KemPharm boasts a robust development pipeline, led by KP1077, and a portfolio of two FDA-approved products, highlighted by AZSTARYS®, once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six years and older.  Central to each of KemPham’s products is a focus on leveraging the company’s proprietary LAT® technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Our Value Proposition

KemPharm® believes that its LAT® technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Learn More

KemPharm’s prodrug product candidate pipeline is focused on the high need areas of idiopathic hypersomnia and other CNS/rare diseases.

We employ our LAT® (Ligand Activated Therapy) technology to improve the attributes of approved drugs.

Learn more about LAT®

May 16, 2022

Featured Publication

KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease  KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration (FDA) as early as the First […]

keep reading

KemPharm® Company Overview
KemPharm® Company Culture

  • 28

    Sep

    22

  • KemPharm Announces Positive Topline Data from...

  • 01

    Sep

    22

  • KemPharm to Present at the H.C. Wainwright 24...

  • 11

    Aug

    22

  • KemPharm Reports Second Quarter 2022 Financia...